Immunome (IMNM) Shares Outstanding (Diluted Average) (2020 - 2026)

Immunome has reported Shares Outstanding (Diluted Average) for 7 years, with the latest figure at $113.1 million in Q1 2026.

• For the quarter ending Q1 2026, Shares Outstanding (Diluted Average) rose 42.47% year-over-year to $113.1 million; the trailing twelve-month figure through Mar 2026 stood at $113.1 million (up 42.47% YoY), and the FY2025 full-year result was $87.4 million, up 48.96% from the prior year.
• Shares Outstanding (Diluted Average) for Q1 2026 stood at $113.1 million, up from $87.4 million in the prior quarter.
• The five-year high for Shares Outstanding (Diluted Average) was $113.1 million in Q1 2026, with the low at $12.1 million in Q1 2022.
• Historically, Shares Outstanding (Diluted Average) has averaged $46.1 million across 5 years, with a median of $51.5 million in 2024.
• Annual changes were most pronounced in 2023 — Shares Outstanding (Diluted Average) gained 0.49% — and 2024, when it surged 391.68%.
• Immunome's Shares Outstanding (Diluted Average) stood at $12.1 million in 2022, then surged by 63.64% to $19.8 million in 2023, then jumped by 195.51% to $58.6 million in 2024, then soared by 48.96% to $87.4 million in 2025, then gained by 29.52% to $113.1 million in 2026.
• The last three Shares Outstanding (Diluted Average) figures came in at $113.1 million (Q1 2026), $87.4 million (Q4 2025), and $88.0 million (Q3 2025), per Business Quant data.